Dermatology

Most molluscum contagiosum lesions resolve on their own, but symptomatic or cosmetically troubling cases have long been managed with off-label agents and destructive procedures. That changed with the FDA approval of cantharidin 0.7% drug-device applicator in 2023 and berdazimer 10.3% gel in 2024. This review examines the trial evidence behind both, compares them with potassium hydroxide, salicylic acid, cryotherapy, curettage, and pulsed dye laser, and addresses the treatment gaps that remain in immunocompromised patients and those with atopic dermatitis.

The skin has long been read as a mirror of internal disease, but its relationship with bone is less familiar. Dermis and bone share a common embryonic origin, overlapping cell lineages, and collagen as a structural backbone. This review examines the skin-bone axis — vitamin D signalling, cystatin A, inflammatory dermatoses, corticosteroid effects on bone, cutaneous signs of metabolic and autoinflammatory bone disease, and the gut microbiome's role in both — and makes the case for a multidisciplinary approach to healthy aging.

Update on Dupilumab for SC injection (Dupixent®) and Adapalene 0.1% + benzoyl peroxide 2.5% acne treatment (Differin® Epiduo® Acne Gel). Also, in June 2026, bemotrizinol – long used internationally as Tinosorb® S – has become the first new FDA‑approved sunscreen filter in over 20 years.

Exosomes are emerging as a promising biologic platform in dermatology, with growing evidence supporting their role in wound healing, skin regeneration, pigmentation control, and inflammatory skin disorders through immune modulation and tissue repair mechanisms.

Discover how zasocitinib, a next-generation selective TYK2 inhibitor, may redefine psoriasis treatment with targeted efficacy, reduced off-target JAK effects, and promising late-stage clinical results.

Update on Icotrokinra 200 mg tablet (Icotyde™), Difamilast 1% ointment (Adquey™), and Epinephrine nasal spray 2 mg/0.1 mL (Neffy®).

Review of topical ruxolitinib as a promising JAK inhibitor for mild to moderate hidradenitis suppurativa, including early trial results, safety data, and its role in addressing unmet treatment needs.

Read about current and emerging hyperhidrosis treatments including sofpironium bromide, glycopyrronium wipes, botulinum toxin, targeted alkali thermolysis, microwave therapy, and laser options.

Update on Nemolizumab SC injection (Nemluvio®), Gepotidacin tablets (Blujepa®), and Zoliflodacin for oral suspension (Nuzolvence®).

Deuruxolitinib (FDA-approved July 2024) is an oral JAK1/JAK2 inhibitor for severe alopecia areata. Learn about its mechanism, THRIVE-AA trial results showing rapid hair regrowth, safety profile, and how it compares to baricitinib and ritlecitinib.

Discover icotrokinra, a groundbreaking oral peptide that targets the IL-23 receptor to treat moderate-to-severe plaque psoriasis. Clinical trials show it delivers biologic-like skin clearance in a convenient once-daily pill.

Update on Calcipotriene and betamethasone dipropionate cream, 0.005%/0.064% (Wynzora®), Roflumilast foam 0.3% (Zoryve®), Roflumilast cream 0.05% (Zoryve®), and Lidocaine topical system 10% (Bondlido®)

The OX40-OX40 ligand pathway has emerged as a promising therapeutic target for moderate-to-severe atopic dermatitis, offering a novel approach that simultaneously addresses multiple inflammatory pathways involved in disease pathogenesis. This review examines phase II clinical trial data for three monoclonal antibodies targeting this pathway: amlitelimab, rocatinlimab, and telazorlimab.

Neoadjuvant cemiplimab has shown promising results for resectable cutaneous squamous cell carcinoma where surgery may result in significant morbidity. Phase 2 studies demonstrated pathological complete response rates of 51% with event-free survival of 89% at 12 months. The treatment was well-tolerated and may improve surgical outcomes by reducing tumor burden before resection, offering a valuable option for advanced disease.

Update on Guselkumab SC use (Tremfya®), Remibrutinib tablets (Rhapsido®), Pembrolizumab + berahyaluronidase alfapmph SC injection (Keytruda Qlex®), Donidalorsen SC use (Dawnzera), Garadacimab for SC use (Andembry®), and Lifileucel for IV use (Amtagvi®)

Health Canada approved selumetinib in 2022 for treating inoperable plexiform neurofibromas in children with neurofibromatosis type 1. Clinical trials showed 74% of patients experienced significant tumor shrinkage, with improvements in pain and quality of life. The oral MEK inhibitor offers the first targeted therapy for these historically difficult-to-treat nerve tumors.

Upadacitinib shows sustained long-term efficacy and safety for moderate-to-severe atopic dermatitis in 76-week studies. The oral JAK inhibitor maintains 80%+ EASI-75 response rates with manageable side effects, outperforming dupilumab in head-to-head trials while offering faster symptom relief for chronic eczema patients.

Update on Delgocitinib cream (Anzupgo®), Recombinant zoster vaccine (Shingrix®), Sebetralstat tablets (Ekterly®), and Lifileucel for IV infusion (Amtagvi®).

Lebrikizumab is a new IL-13 targeting monoclonal antibody approved for moderate-to-severe atopic dermatitis in patients 12+ years. Learn about clinical trial efficacy, safety data, dosing, and how it compares to other AD biologics like dupilumab and tralokinumab.

Nanodermatology uses nanoparticles (1-1000 nanometers) to enhance transdermal drug delivery for treating psoriasis, vitiligo, acne, and atopic dermatitis. Learn about nanocarriers, liposomes, and how nanotechnology improves topical medication penetration while reducing side effects.

Update on Dupilumab SC injection (Dupixent®), Garadacimab-gxii for SC injection (Andembry®), Roflumilast foam, 0.3% (Zoryve®), Ustekinumab-hmny for SC injection (Starjemza®), Ustekinumab biosimilar SC/IV use (Otulfi®) and Prademagene zamikeracel genemodified cellular sheets (Zevaskyn™).

Nemolizumab, an IL-31 receptor antagonist, has demonstrated high efficacy and a favorable safety profile in phase 3 trials for prurigo nodularis and atopic dermatitis. Patients showed significant reductions in itch, improved skin lesions, and better quality of life over extended treatment periods.

IDP-126 is a novel fixed-dose topical gel combining clindamycin, benzoyl peroxide, and adapalene for moderate to severe acne. Approved by the FDA and Health Canada, it showed superior efficacy over dual therapies in phase 2 and 3 trials, with strong safety and tolerability outcomes.

Update on Tapinarof cream 1% (Nduvra™), Omalizumab-igec for SC injection (Omlyclo®) and Retifanlimab for IV infusion (Zynyz®).

Explore the safety and efficacy of roflumilast 0.3% foam, a novel PDE-4 inhibitor, for treating seborrheic dermatitis. This review evaluates clinical trial outcomes, tolerability, and advantages compared to traditional therapies, highlighting its role as an effective, once-daily non-steroidal treatment option.

Discover the role of IL-23 inhibition in psoriatic arthritis with a detailed review of guselkumab’s efficacy, safety, and practical use. This article summarizes key clinical trial findings, patient outcomes, and compares guselkumab to other biologic treatments, emphasizing its value as an alternative therapeutic option.

Update on Mirdametinib 1 mg tablets for oral suspension & 1 mg/2 mg capsules (Gomekli™), Ustekinumab-stba SC/IV injection (Steqeyma®) and Nivolumab + hyaluronidase-nvhy for SC injection (Opdivo Qvantig™).

Explore a comprehensive overview of pediatric hidradenitis suppurativa (HS), a chronic inflammatory skin condition. This article delves into its epidemiology, pathogenesis, clinical features, associated comorbidities, and treatment challenges. Gain insights into the unique aspects of pediatric HS, including its impact on quality of life and the importance of early diagnosis and management.

Discover the latest insights into managing cutaneous leishmaniasis (CL), including its epidemiology, prevention, diagnosis, and treatment advancements. This article highlights rising global cases, travel-related risks, and evolving clinical strategies to combat this neglected tropical disease.

Update on Cosibelimab-ipdl IV use (Unloxcyt™), Ustekinumab-kfce SC/IV use (Yesintek™), Minocycline hydrochloride capsules (Emrosi™).

Learn about the role of biofilms in skin disorders like acne, atopic dermatitis, and chronic wounds. This article explores how biofilms contribute to disease pathogenesis, their resistance to antibiotics, and the latest conventional and innovative treatments aimed at targeting biofilm-associated skin conditions.

Discover how trifarotene, a fourth-generation retinoid, effectively treats acne and post-inflammatory hyperpigmentation (PIH). Learn about its benefits, clinical evidence, and role in managing acne sequelae.

Update on Ruxolitinib phosphate cream 1.5% (Opzelura®), Roflumilast foam 0.3% (Zoryve®), Clindamycin 1.2%/adapalene 0.15%/benzoyl peroxide 3.1% fixed-dose topical gel (Cabtreo™), Lebrikizumab-lbkz (Ebglyss™ SC injection), Ustekinumab-srlf (Imuldosa™ SC/IV injection), Ustekinumab-aauz (Otulfi™ SC/IV injection), Ustekinumab biosimilar (Pyzchiva™ SC/IV injection).

Comprehensive review of methoxyflurane inhaled analgesia in dermatology, discussing efficacy, safety, and applications in outpatient procedures for effective pain management.

Discover advancements in oral isotretinoin formulations, including micronized isotretinoin, improving bioavailability and reducing food dependency for optimal acne treatment outcomes.

Update on Nemolizumab-ilto SC injection (Nemluvio®), Denileukin diftitox-cxdl IV use (Lymphir™), Deuruxolitinib phosphate tablets (Leqselvi™), Roflumilast cream (Zoryve™), Ustekinumab-ttwe SC/IV injectio (Pyzchiva®), Sofpironium gel, 12.45% (Sofdra™), Ustekinumab biosimilar (Steqeyma® SC/IV injection) and Lebrikizumab SC injection (Ebglyss™)

Review of the effectiveness of trifarotene, a novel retinoid, in managing atrophic acne scars, highlighting its targeted action on retinoid acid receptor gamma (RAR-γ) and presenting recent clinical data supporting its use as a valuable adjunct treatment for acne scarring.

Explore the role of hormones in managing adult female acne with insights from Dr. Jennifer Lipson. Understand the pathophysiology, prevalence, and impact of hormonal therapies including oral contraceptives, spironolactone, and new topical treatments like clascoterone cream. Discover effective strategies for targeting hormones to treat this common and challenging condition.

Update on Adalimumab-adbm for SC injection (Cyltezo®), Secukinumab for SC injection (Cosentyx®), Tirbanibulin 1% ointment (Spevigo™), LetibotulinumtoxinA-wlbg IM use (Letybo™), and Bimekizumab SC use (Bimzelx®).

This article reviews the use of intravenous immunoglobulin (IVIG) in dermatology, highlighting its role in treating autoimmune and inflammatory skin diseases. It discusses how IVIG reduces the need for steroids or immunosuppressants and its applications in conditions such as autoimmune bullous dermatoses, dermatomyositis, and Stevens-Johnson syndrome. The article also addresses dosing regimens, potential adverse effects, and the importance of ongoing research to further understand the efficacy and safety of IVIG in dermatologic treatments.